PIPELINE
What we develop
Nuravax is on a trajectory of significant growth and advancement
By the end of 2024, we anticipate doubling our fully FDA-cleared Investigational New Drugs (INDs). This milestone is the result of 18 years of dedicated effort by the Nuravax and IMM teams, who have developed and refined our 3rd generation platform. Our focus has been on creating multiple vaccines for individuals at risk of Alzheimer’s disease, tauopathies, Parkinson’s disease, and α-synucleopathies. This development has been substantially supported by NIA and NINDS grants, including R21s, R01s, and U01 awards.
Current Status of IND / pre-IND products (vaccines)
1
2
3
4
CANDIDATE
DISCOVERY
PRE-CLINICAL STUDIES
SAFETY / TOXICOLOGY
IND
PHASE 1
PHASE 2
PHASE 3
AV-1959D
(Abeta DNA vaccine)
(Abeta DNA vaccine)
AV-1980R
(Tau Recom vaccine)
(Tau Recom vaccine)
AV-1959R
(Abeta Recom vaccine)
(Abeta Recom vaccine)
Duvax
Phase 1 ongoing
Protein vaccine
5
PV-1950
(Parkinson's disease)
(Parkinson's disease)
IND Cleared
Our non-clinical trials have yielded encouraging results. In studies with transgenic animal models, vaccination using our beta-amyloid, tau, and a-syn vaccines led to the production of highly potent antibody titers. This resulted in a substantial reduction in the accumulation of beta-amyloid plaques, tau tangles, and oligomers. Furthermore, these vaccines demonstrated efficacy in reducing the activation of microglia and astrocytes, crucial brain cells, without causing an increase in microhemorrhages.
Comparative studies have also revealed that antibody levels in the blood of vaccinated animals were significantly higher than those observed with some other vaccines currently in clinical trials. These findings highlight the potential of our vaccines in offering a new avenue for the treatment of neurodegenerative conditions.
Comparative studies have also revealed that antibody levels in the blood of vaccinated animals were significantly higher than those observed with some other vaccines currently in clinical trials. These findings highlight the potential of our vaccines in offering a new avenue for the treatment of neurodegenerative conditions.
Promising Non-Clinical Trial Outcomes